Tyra Biosciences, Inc. — Director's Dealing 2021

Sep 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-17

Reporting Person: MORE ROBERT J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-17	Common Stock	C	3811117	—	Acquired	3924046	Indirect
2021-09-17	Common Stock	P	156250	$16.00	Acquired	4080296	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-17	Series A Preferred Stock	$	C	1212122	Disposed		Common Stock (3148365)	Indirect
2021-09-17	Series B Preferred Stock	$	C	255160	Disposed		Common Stock (662752)	Indirect

Footnotes

F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.